Editing Muscle-Invasive Bladder Cancer (section)

====== <span style="color:#ff00ff">LEA AUO AB 25/02 (European Urology 2019)</span> ======

* Population: 401 patients with locally resectable T1G3 or muscle-invasive urothelial bladder cancer (T2-T4aM0)
* '''Randomized to limited''' (obturator, and internal and external iliac nodes) '''vs. extended LND''' (in addition, deep obturator, common iliac, presacral, paracaval, interaortocaval, and para-aortal nodes up to the inferior mesenteric artery).
* Primary outcome: recurrence-free survival
* Secondary outcomes: cancer-specific survival, overall survival, complications
* Results:
** Median number of dissected nodes: limited 19 vs. extended 31
** '''Primary outcome: no significant difference in recurrence-free survival''' (5-yr RFS 65% extended vs 59%; p=0.36)
** Secondary outcomes:
*** No significant difference in cancer-specific survival (5-yr CSS 76% vs 65%; p=0.10)
*** No significant difference in overall survival (5-yr OS 59% vs 50%; p=0.12)
*** Clavien grade ≥3 lymphoceles were more frequently reported in the extended LND group within 90 days after surgery.
* [https://pubmed.ncbi.nlm.nih.gov/30337060/ Gschwend, Jürgen E., et al.] "Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial." European urology 75.4 (2019): 604-611.